Purpose: This study aimed to determine whether clinicopathological factors are potentially associated with successful breast-conserving surgery (BCS) after neoadjuvant chemotherapy (NAC) and develop a nomogram for predicting successful BCS candidates, focusing on those who are diagnosed with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative tumors during the pre-NAC period. Methods: The training cohort included 239 patients with an HR-positive, HER2-negative tumor (≥ 3 cm), and all of these patients had received NAC. Patients were excluded if they met any of the following criteria: diffuse, suspicious, malignant microcalcification (extent > 4 cm); multicentric or multifocal breast cancer; inflammatory breast cancer; distant metastases at the time of diagnosis; excisional biopsy prior to NAC; and bilateral breast cancer. Multivariate logistic regression analysis was conducted to evaluate the possible predictors of BCS eligibility after NAC, and the regression model was used to develop the predicting nomogram. This nomogram was built using the training cohort (n= 239) and was later validated with an independent validation cohort (n= 123). Results: Small tumor size (p< 0.001) at initial diagnosis, long distance from the nipple (p= 0.002), high body mass index (p= 0.001), and weak positivity for progesterone receptor (p= 0.037) were found to be four independent predictors of an increased probability of BCS after NAC; further, these variables were used as covariates in developing the nomogram. For the training and validation cohorts, the areas under the receiver operating characteristic curve were 0.833 and 0.786, respectively; these values demonstrate the potential predictive power of this nomogram. Conclusion: This study established a new nomogram to predict successful BCS in patients with HR-positive, HER2-negative breast cancer. Given that chemotherapy is an option with unreliable outcomes for this subtype, this nomogram may be used to select patients for NAC followed by successful BCS.
INTRODUCTION
From a surgeon's perspective, treating breast cancer patients with neoadjuvant chemotherapy (NAC) provides two major clinical advantages. Firstly, it permits control of locally advanced or inflammatory tumors that cannot be resolved with surgical therapy alone; secondly, it enables breast-conserving surgery (BCS) by reducing the tumor size.
There exists no disagreement about the role of NAC as the standard of care in locally advanced or inflammatory breast cancer [1] [2] [3] [4] ; however, when considering NAC in early breast cancer treatment to reduce the tumor size, there are not many predictors known for successful conservative surgery [3] [4] [5] .
Tumor biology, that is, subtypes practically determined by estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are strong predictors of successful, less invasive surgical approaches after NAC. In a prospective multicenter clinical trial, patients with triple-negative and HER2-positive tumors were found to have high rates of BCS after NAC (46.8% and 43%, respectively) than those with hormone receptor (HR)-positive, HER2-negative tumors (34.5%) [5] . Based on the nomograms predicting whether a patient would be eligible for BCS after NAC [3, 4] and data from the U.S. National Cancer Database [6] , ER negativity is considered to be one of the key factors associated with a high probability of successful breast conservation. Accordingly, surgeons expect that ORIGINAL ARTICLE Luminal Subtype Specific Nomogram for Predicting BCS after NAC 53 large HR-positive and HER2-negative tumors will respond poorly to NAC, subsequently limiting the eligibility for BCS in these patients.
Despite the clinical need for more detailed studies with this HR-positive, HER2-negative subtype, very few reliable factors have been identified so far.
It is challenging for surgeons to identify the eligible BCS candidates within the HR-positive and HER2-negative subtype. However, with the assistance of novel genomic assays, careful considerations can be made about treatment strategies for HR-positive, HER2-negative cancer. Based on chemosensitivity and breast cancer mortality, adjuvant chemotherapy should be avoided in selected patients, including women with limited node metastasis [7] [8] [9] . For patients representing this subtype and fulfilling the criteria for BCS (except for tumor size), the decision about the appropriateness of NAC can become even more challenging for surgeons.
The first aim of this study was to determine whether the clinicopathologic factors are potentially associated with successful BCS following NAC. Secondly, we aimed to develop a nomogram predicting successful BCS candidates, especially involving those who were diagnosed with HR-positive, HER2-negative tumors during the pre-NAC period.
METHODS

Study population
The anonymized database of the Asan Medical Center was reviewed to identify stage II/III HR-positive, HER2-negative breast cancer patients who had received NAC followed by surgery between February 2008 and December 2014. This study included patients with an HR-positive, HER2-negative tumor (≥ 3 cm in size) and had received NAC. We excluded the cases with multicentric tumors or diffuse, suspicious, malignant microcalcification because these factors are generally expected to remain unresolved despite NAC and rarely influence the possibility of conversion from BCS-ineligible to BCS-eligible after NAC. Therefore, patients were excluded if they had diffuse suspicious malignant microcalcification (extent > 4 cm) and multicentric or multifocal breast cancer. Patients with the following characteristics were also excluded: inflammatory breast cancer, distant metastases at the time of diagnosis, excisional biopsy prior to NAC, and bilateral breast cancer. Finally, a total of 239 patients were included in our study, and we retrospectively collected information regarding basic demographics as well as clinical, radiological, and pathological factors. After building a nomogram with this cohort, an independent cohort of patients (n =123) was employed to validate the results of the nomogram. The selection of all the patients in the validation set was based on the same inclusion and exclusion criteria as the training set.
Between January 2015 and August 2017, these patients also received NAC followed by surgery at the same institution. 
Statistical analysis
Correlations between the definitive surgery type and several categorical variables were evaluated using the chi-square test. For continuous variables such as age, body mass index (BMI), initial tumor size, and distance from the nipple, a t-test was used for comparing the means of BCS and total mastectomy groups. Multivariate logistic regression analysis was conducted to evaluate possible predictors for BCS eligibility after NAC. A stepwise variable selection was performed to include significant independent variables in the model.
Subsequently, we developed a regression model-derived nomogram
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by employing a training cohort (n =239) and further validated with another independent cohort (n =123). The model performance was assessed with respect to discrimination, which was quantified with the concordance index, identical to the area under the receiver operating characteristics (ROC) curve. Unless stated otherwise, the data are presented as the mean ± standard deviation, and the cutoff for statistical significance is set at p < 0.05. All statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, USA), STATA version 13 (StataCorp., College Station, USA), and open source R version 3.4.
RESULTS
The age of the entire training cohort (n =239 patients) was 45.2± 9.6 years (range, 23-72 years), and the initial tumor size was 5.3± 1.7 cm (range, 3.1-11.8 cm). There were 141 patients (59.0%) detected with positive nodes during preoperative diagnosis, and 15 patients (6.3%) achieved a complete pathological response (pCR) to NAC. For NAC regimens, four cycles of adriamycin along with cyclophosphamide every 3 weeks (AC) or four cycles of adriamycin combined with cyclophosphamide every 3 weeks followed by four cycles of docetaxel every 3 weeks (AC-D) was given to 86 (36.0%) and 116 (48.5%) patients, respectively. The details of the patient characteristics are provided in Table 1. Table 2 summarizes the baseline characteristics of patients undergoing BCS and total mastectomy. BMI, initial tumor size, clinical nodal status, histologic grade, ER status, the regimen of chemotherapy, malignant calcification, and distance from the nipple were significantly different between the two groups.
The results of the multivariate logistic regression analysis (Table 3) demonstrated that the four variables including initial tumor size (p < 0.001), distance from the nipple (p = 0.002), BMI (p = 0.001), and PR (p = 0.037) were independent predictors of an increased probability of BCS after NAC. These variables (small tumor size at the initial diagnosis, long distance from the nipple, high BMI, and weak PR positivity) were related to successful BCS after NAC. Thus, these predictors were used to develop a predicting nomogram (Figure 1 ). Each predictor and corresponding point are presented in Table 4 . Using these four predictors, we calculated total scores and assigned probabilities of successful BCS for each patient either by directly reading displayed values in Table 4 or via approximate graphical computation as shown in Figure 1 . Figure 2 shows the ROC curves that were used to determine the discrimination power of the nomogram. These curves were applied to the training dataset (n =239 patients) with known values or status of BCS = breast-conserving surgery; TM = total mastectomy; BMI = body mass index; AC = adriamycin+cyclophosphamide; D = docetaxel; pCR = pathologic complete response. *Mean ± SD (range). -35  48  12  0  --167  0.95  --36  50  --------37  53  --------38  56  --------39  58  --------40  61  --------41  64  ------ http://www.jbd.or.kr
Luminal Subtype Specific Nomogram for Predicting BCS after NAC 57 all four predictors, and they were later applied to the independent validation dataset (n =123 patients). The areas under the ROC curve (AUCs) were 0.833 and 0.786, respectively, and these values demonstrated a strong predictive power of this nomogram.
DISCUSSION
In this study, we identified four factors (i.e., small initial tumor size, Compared with previous studies involving patients with all types of breast cancer and identifying the subtype as a key predictor [3] [4] [5] [6] 12, 13] , the current study has valuable implications because our nomogram can be specifically applied to patients with HR-positive, HER2-negative cancer, which is believed to be less responsive to NAC and has a low probability of successful BCS.
At the initial diagnosis, the appearance of a small tumor is intuitively understood as a predictor of successful BCS. This enables surgeons to make a decision favoring BCS; further, tumor size has been consistently reported as being significant in other nomograms [3, 4] . Long distance from the nipple enhances the ability to conserve the nipple-areolar complex (NAC) and also encourages surgeons to recommend BCS. Undoubtedly, central lumpectomy with resection of NAC may be chosen as a safe and cosmetic surgical option; however, this decision depends on a surgeon's preference [14, 15] . Therefore, it is recommended that at institutes where central lumpectomy is more frequently performed, the significance of distance of tumor from the nipple should be cautiously re-examined. Patients with high BMI have increased risks of receiving BCS, possibly because BMI is significantly associated with breast volume; further, it is known that the breast volume is two-three times greater in overweight and obese women (with high BMI) than in women with normal BMI [16] . Contrary to our results, in the previously presented Seoul National University Hospital (SNUH) nomogram, Kim et al. [4] reported that the breast volume was not a predictive factor for BCS. These results may have been influenced by either the two-dimensional, mammogram-based method used in this study [17] There are several limitations of this study worth noting. This study was performed using retrospective data, and treatment was not assigned in a randomized fashion. In addition, there might be a bias in predicting BCS because patients' preferences for BCS are not reflected in this study, and patients who underwent total mastectomy followed by immediate reconstruction are also included in this cohort. In future, a detailed and planned survey of the surgery type in a prospective setting may provide a nomogram with improved predictive capabilities.
In conclusion, this study establishes a new nomogram to predict successful BCS in patients with HR-positive, HER2-negative breast cancer. Given that chemotherapeutic response is unpredictable for this subtype of breast cancer, our nomogram can be useful in selecting the patients who will benefit from NAC followed by successful BCS.
